Demeter Therapeutics is a privately-held biopharmaceutical company focused on developing treatments for rare and ultra-rare diseases. We pay particular attention to debilitating genetic disorders impacting mitochondrial function. Founded in 2015, Demeter's leadership has leveraged knowledge of mitochondrial biology with targeted chemistry to build a diverse portfolio of preclinical candidates. These therapeutic moities have the potential to address mitochondrial diseases via well understood pharmacological mechanisms. We are committed to bringing these therapies to patients in need.